yd12399云顶集团(中国)有限公司

Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy

CN

Our Products News

Phase II/III study of optic neuroprotective oligonucleotide therapeutics QPI-1007 completed dosing of the first subject in China

Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. announced that in the global pivotal II/III study QRK207 of its innovative siRNA drug QPI-1007 for optic nerve protection, the investigational product has been administered to the first subject by Professor Wang Ningli's team at Beijing Tongren Hospital, Capital Medical University, China.

November 13, 2017

4